Your heart is a muscle. As Dr. Noah Moss, an advanced heart failure and transplant cardiologist at the Mount Sinai Fuster Hospital in New York City, puts it, “a very special muscle, but a muscle.” ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Hypertrophic cardiomyopathy (HCM) is a condition where some of the heart muscle becomes too thick, (a.k.a., hypertrophied, a typical diagnostic criterion is a 15 millimeters or greater left ventricle ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Hypertrophic obstructive cardiomyopathy (HOCM or HCM) is a rare, usually inherited condition in which children develop too much muscle in the left chamber of the heart, the one which pumps blood ...

The Hypertrophic Cardiomyopathy (HCM) Program at University of Utah Health is one of the nation’s few programs for comprehensive HCM evaluation and management. Our multidisciplinary team works ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...